The Second Multicenter Hemophilia Cohort Study
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00341705 |
Recruitment Status
:
Completed
First Posted
: June 21, 2006
Last Update Posted
: April 20, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Liver Decompensation Hepatocellular Carcinoma Non-Hodgkin Lymphoma |
Study Type : | Observational |
Actual Enrollment : | 2565 participants |
Official Title: | The Second Multicenter Hemophilia Cohort Study |
Study Start Date : | April 27, 2001 |
Study Completion Date : | April 2, 2013 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 13 Years and older (Child, Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
- INCLUSION CRITERIA:
Must be registered patient with an inherited coagulation disorder at a participating MHCS-II center. Disorders include hemophilia A or B (congenital factor VIII or IX deficiency), deficiencies in other factors such as V or XI, and vonWillebrand's disease. (Unless noted otherwise, all of the disorders will collectively be referred to as hemophilia .) All such hemophilia and vonWillebrand s disease patients are to be recruited as study participants.
Since January 1, 1993, must have had at least one positive result on a licensed assay for HCV antibodies, HIV antibodies, or HIV RNA.
Must be at least 13 years of age at enrollment.
Must provide signed informed consent or, for minors, signed assent plus signed informed consent from the parent or guardian.
EXCLUSION CRITERIA:
Is not a patient with an inherited coagulation disorder.
Does not have a positive test for HCV antibodies, HIV antibodies, or HIV RNA on a licensed assay performed since January 1, 1993.
Is less than 13 years of age.
Lacks informed consent/assent.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00341705

Principal Investigator: | James J Goedert, M.D. | National Cancer Institute (NCI) |
Publications:
ClinicalTrials.gov Identifier: | NCT00341705 History of Changes |
Other Study ID Numbers: |
999901170 01-C-N170 |
First Posted: | June 21, 2006 Key Record Dates |
Last Update Posted: | April 20, 2018 |
Last Verified: | April 2, 2013 |
Keywords provided by National Institutes of Health Clinical Center (CC):
AIDS Cancer Hepatitis C Virus HIV |
Natural History Hemophilia Hepatitis C |
Additional relevant MeSH terms:
Lymphoma, Non-Hodgkin Carcinoma, Hepatocellular Hemophilia A Liver Failure Lymphoma Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Adenocarcinoma Carcinoma |
Neoplasms, Glandular and Epithelial Liver Neoplasms Digestive System Neoplasms Neoplasms by Site Digestive System Diseases Liver Diseases Blood Coagulation Disorders, Inherited Blood Coagulation Disorders Hematologic Diseases Coagulation Protein Disorders Hemorrhagic Disorders Genetic Diseases, Inborn Hepatic Insufficiency |